Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome
Restricted accessLetterFirst published online October, 2011
Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome
ExnerT. Comparison of two simple tests for the lupus anticoagulant. Am J Clin Pathol1985; 83: 215–218.
2.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
3.
RoccatelloDBaldovinoSRossiD. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol2008; 34: 111–117.
4.
SatomiAKoiwaFOgataH. Plasma exchange for thrombocytopenia in antiphospholipid syndrome: a case report. Ther Apher1998; 2: 157–159.
5.
LimWCrowtherMAEikelboomJW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA2006; 295: 1050–1057.
6.
ErreGLPardiniSFaeddaRPassiuG. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus2008; 17: 50–50.
7.
IoannouYLambrianidesACambridgeGLeandroMJEdwardsJCIsenbergDA. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis2008; 67: 425–426.
8.
VlachoyiannopoulosPGToyaSPKatsifisG. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus. J Rheumatol2008; 35: 1768–1775.
